

# The Properties of Specific Binding Site of 125I-Radioiodinated Myotoxin , a Novel Ca<sup>++</sup> Releasing, agent in Skeletal Muscle Sarcoplasmic Reticulum

著者	Ohkura M., Furukawa K. -I., Oikawa K., Ohizumi Y.
journal or publication title	CYRIC annual report
volume	1995
page range	115-117
year	1995
URL	<a href="http://hdl.handle.net/10097/49919">http://hdl.handle.net/10097/49919</a>

### III. 10. The Properties of Specific Binding Site of <sup>125</sup>I-Radioiodinated Myotoxin *a*, a Novel Ca<sup>++</sup> Releasing, agent in Skeletal Muscle Sarcoplasmic Reticulum

*Ohkura M., Furukawa K.-I., Oikawa K. and Ohizumi Y.*

*Department of Pharmaceutical Molecular Biology, Faculty of Pharmaceutical Sciences,  
Tohoku University*

#### Introduction

Myotoxin *a* (MYTX) isolated from prairie rattlesnakes (*Crotalus viridis viridis*) is a muscle-damaging polypeptide that is composed of 42 amino-acid residues including 3 disulfide bonds<sup>1</sup>). The electron-microscopic study has revealed that MYTX causes muscle degeneration and disturbance of the sarcoplasmic reticulum (SR) functions and muscle filaments<sup>2</sup>). Recently, we found that MYTX strongly induced Ca<sup>++</sup> release from skeletal muscle SR with the EC<sub>50</sub> value of 0.5 μM. The properties of MYTX-induced Ca<sup>++</sup> release were different from those induced by the other Ca<sup>++</sup>-releasing agents such as caffeine, MBED, a powerful caffeine-like Ca<sup>++</sup> releaser, and adenosine 5'-(β,γ-methylene)triphosphate (AMP-PCP)<sup>3</sup>).

In order to characterize the molecular mechanism of action of MYTX, we prepared <sup>125</sup>I-labeled MYTX (<sup>125</sup>I-MYTX), and studied its binding to the heavy fraction of fragmented SR (HSR), in which the ryanodine receptor is enriched abundantly. Our results indicated that MYTX induced Ca<sup>++</sup> release by binding to a specific site which is distinct from the ryanodine receptor. MYTX may be useful as a biochemical probe not only for clarifying the regulatory mechanism of physiological Ca<sup>++</sup> release but also for purifying a novel type of Ca<sup>++</sup> release channels or their regulatory proteins.

#### Materials and Methods

##### MATERIALS

HSR was prepared from rabbit skeletal muscle by the method of Kim et al.<sup>4</sup>). The ryanodine receptor was purified from skeletal muscle by the method of Shoshan-Barmatz and Zarka<sup>5</sup>). MBED was synthesized by the method described previously<sup>6,7</sup>). Chemicals used were obtained from following sources; crude venom of prairie rattlesnakes (*Crotalus viridis viridis*) from Sigma; ryanodine from S.B. Penick Company; <sup>45</sup>CaCl<sub>2</sub> (25.9 Bq/pmol), <sup>3</sup>H-

ryanodine (2.22 kBq/pmol) and Na<sup>125</sup>I (95.3 kBq/pmol) from Du-Pont New England Nuclear; All other chemicals were of reagent grade.

## METHODS

MYTX (Fig. 1) was purified as described previously<sup>2</sup>). <sup>125</sup>I-Labeling of MYTX was performed by the chloramine T method. <sup>125</sup>I-MYTX binding was measured by the method of Penefsky<sup>8</sup>) with a slight modification. <sup>3</sup>H-Ryanodine binding was measured as described previously<sup>7</sup>). The extravesicular Ca<sup>++</sup> concentration was monitored with a Ca<sup>++</sup> electrode prepared by the method of Nakamura et al.<sup>9</sup>). <sup>45</sup>Ca<sup>++</sup> release from HSR passively preloaded with <sup>45</sup>Ca<sup>++</sup> was measured at 0°C as described previously<sup>9</sup>) with a slight modification.

## Results and Discussion

It was found that MYTX is a powerful Ca<sup>++</sup> releaser in the HSR. <sup>125</sup>I-MYTX with high Ca<sup>++</sup>-releasing ability was successfully prepared. It specifically bound to a single class of binding sites in HSR with a K<sub>D</sub> of 0.4 μM and B<sub>max</sub> of 6 nmol/mg protein (Fig.1). <sup>125</sup>I-MYTX binding was markedly inhibited by Na<sup>+</sup> and K<sup>+</sup>, whereas that was little affected by Ca<sup>++</sup> and Mg<sup>++</sup>. The binding activity was markedly decreased by spermine, a blocker of Ca<sup>++</sup> release channels, and was not affected by the other modulators of Ca<sup>++</sup> release such as caffeine, procaine or ruthenium red (Table 1). Spermine decreased the binding in a concentration-dependent manner with the IC<sub>50</sub> value of 20 μM. Scatchard analysis of <sup>125</sup>I-MYTX binding indicated that the B<sub>max</sub> value was decreased by spermine, while the K<sub>D</sub> value was not changed, indicating a noncompetitive mode of inhibition. <sup>125</sup>I-MYTX did not bind to the purified ryanodine receptor. Ca<sup>++</sup> electrode experiments indicated that MYTX induced Ca<sup>++</sup> release from HSR at 0.1 μM or more, which was abolished by spermine. The maximal response to MYTX (10 μM) was further increased by caffeine (10 μM) in <sup>45</sup>Ca<sup>++</sup> release, probably indicating that the effects of MYTX and caffeine are synergistic in Ca<sup>++</sup>-releasing action (Fig. 2). These results suggest that MYTX binds to an important regulatory protein of Ca<sup>++</sup> release which is not the ryanodine receptor.

## References

- 1) Fox J. W. et al., *Biochemistry* **18** (1979) 678.
- 2) Cameron D. L. and Tu A. T., *Biochemistry* **224** (1977) 89.
- 3) Funayama K. et al., *Jpn. J. Pharmacol.* **58** (1992) suppl. I, 208P.
- 4) Kim D. H. et al., *J. Biol. Chem.* **258** (1983) 9662.
- 5) Shoshan-Barmatz V. and Zarka A., *Biochem. J.* **285** (1992) 61.
- 6) Kobayashi J. et al., *J. Pharm. Pharmacol.* **40** (1988) 62.
- 7) Seino A. et al., *J. Pharmacol. Exp. Ther.* **256** (1991) 861.
- 8) Penefsky H. S., *Methods Enzymol.* **56** (1979) 527.
- 9) Nakamura Y. et al., *J. Biol. Chem.* **261** (1986) 4139.

Table 1. Effects of various modulators of Ca<sup>2+</sup> release on <sup>125</sup>I-MYTX binding to HSR. HSR vesicles (50 µg/ml) were incubated with <sup>125</sup>I-MYTX (0.3 µM) at 0° C for 60 min in the presence or absence (control) of various modulators. Values, expressed as percents of control, are means ± S.E.M. (n = 3). Significantly different from control: \*\* (p < .01).

Modulators	<sup>125</sup> I-MYTX Bound % of Control
Control	100.0 ± 2.63
Caffeine (2 mM)	93.5 ± 10.10
MBED (10 µM)	106.5 ± 1.36
AMP-PCP (100 µM)	100.1 ± 6.22
Inositol (1,4,5)trisphosphate (10 µM)	104.1 ± 2.80
Procaine (10 mM)	113.4 ± 5.93
Ruthenium red (1 µM)	96.2 ± 2.66
Spermine (100 µM)	31.0 ± 3.78*
Dantrolene (10 µM)	98.8 ± 3.22




Fig. 1. Saturation (A) and Scatchard (B) plots of <sup>125</sup>I-MYTX binding to HSR. HSR (50 µg/ml) was incubated with <sup>125</sup>I-MYTX at various concentrations at 0° C for 60 min. Values are means with S.E.M. (n=3).




Fig. 2. Interrelations between the Ca<sup>2+</sup>-releasing activities of MYTX and caffeine in <sup>45</sup>Ca<sup>2+</sup> release experiments on HSR. The <sup>45</sup>Ca<sup>2+</sup> content of HSR was measured at 0° C by the filtration method. Values are means with S.E.M. (n = 3). Control (O); MYTX (10 µM) (●); caffeine (10 mM) (▲); MYTX (10 µM) plus caffeine (10 mM) (■).